GENERALIZED PUSTULAR PSORIASIS
Clinical trials for GENERALIZED PUSTULAR PSORIASIS explained in plain language.
Never miss a new study
Get alerted when new GENERALIZED PUSTULAR PSORIASIS trials appear
Sign up with your email to follow new studies for GENERALIZED PUSTULAR PSORIASIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising drug calms rare skin Flare-Ups in small study
Disease control CompletedThis study tested a drug called imsidolimab in 8 adults with active generalized pustular psoriasis (GPP), a rare and painful skin condition that causes widespread pus-filled blisters. The goal was to see if the drug could safely reduce symptoms like redness, swelling, and pustule…
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Phase: PHASE2 • Sponsor: Vanda Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 05:09 UTC
-
New hope for rare skin disease: drug calms severe flare-ups
Disease control CompletedThis program provided a medicine called spesolimab to 39 people in China with a serious skin disease, generalized pustular psoriasis (GPP), who had no other treatment options. Participants received a single infusion of the drug into a vein, with a possible second dose one week la…
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
One-Dose wonder? new drug clears pustules in rare psoriasis flare
Disease control CompletedThis study tested a single dose of spesolimab in 53 people with generalized pustular psoriasis (GPP) having a severe flare. The goal was to see if it could quickly clear visible pustules within a week compared to a placebo. Results showed spesolimab helped more patients achieve c…
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New drug spesolimab tracked in Real-World GPP patients
Disease control CompletedThis study monitored 52 Japanese patients with generalized pustular psoriasis (GPP) who received spesolimab for acute symptoms. The goal was to track side effects and see how the drug works in everyday medical practice. All participants had never used spesolimab before.
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New drug shows promise for rare, severe psoriasis flares
Disease control CompletedThis study tested a new medicine called imsidolimab for adults with a rare and severe form of psoriasis that causes painful pus-filled bumps all over the body. The goal was to see if the drug could clear or nearly clear the skin compared to a placebo. The trial involved 45 partic…
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Phase: PHASE3 • Sponsor: Vanda Pharmaceuticals • Aim: Disease control
Last updated May 04, 2026 16:20 UTC
-
Breakthrough shot may stop rare psoriasis flares before they start
Prevention CompletedThis study tested whether a monthly injection of spesolimab can prevent sudden, severe flare-ups of generalized pustular psoriasis (GPP), a rare and painful skin condition. 123 people aged 12 to 75 with clear or nearly clear skin joined the trial. They received either one of thre…
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Prevention
Last updated May 15, 2026 11:56 UTC